Contradictions in DAYBUE and NUPLAZID Growth: Insights from the Latest Earnings Call

Revenue Growth and Commercial Performance:
- Acadia Pharmaceuticals reported total revenue of $264.6 million in Q2 2025, driven by strong growth across its portfolio, with DAYBUE contributing $96.1 million and NUPLAZID $168.5 million.
- Growth was attributed to increasing patient uptake for DAYBUE, stabilization and expansion phases, and continued momentum for NUPLAZID with new patient starts and commercial execution.

DAYBUE Patient Uptake and Persistency:
- DAYBUE's Q2 sales were $96.1 million, up 14% year-over-year, with 987 unique patients receiving paid shipments, reflecting a steady growth in new patient starts and persistency.
- The trend is supported by field force expansion, increased community-based prescriptions, and an 18-month persistency rate above 45%.

NUPLAZID Sales and Market Expansion:
- NUPLAZID's Q2 sales were $168.5 million, up 7% year-over-year, due to a 17% increase in referrals and sequential growth in new prescriptions.
- The growth is attributed to successful direct-to-consumer campaigns and legal victories enforcing intellectual property rights.

Pipeline and R&D Progress:
- Acadia's pipeline includes 9 disclosed programs with 7 Phase II or Phase III studies expected in 2025 and 2026, and 5 Phase II or Phase III data readouts expected by 2027.
- Progress is supported by significant contributions to scientific literature and strong interest in global expansion, as highlighted by events like the first R&D Day.